$DKNG

Needham’s $30 Target Says DraftKings’ Selloff Went Too Far

Needham reduced its price target for DraftKings to $30 from $35, maintaining a Buy rating. The stock has fallen 42% since January due to spending on prediction markets and competition from rivals like Kalshi. At $30, DraftKings would trade at 29x expected earnings, with analysts forecasting earnings to double by 2027. The company's Nov. 6 call will provide further clarity on 2027 earnings.

Original reporting
Published Nov 2, 2026, 6:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 7:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Needham’s $30 Target Says DraftKings’ Selloff Went Too Far — source image
Decision brief

The 30-second read

$DKNGNeutralMed
01

Why it matters

Analyst target reduction reflects concerns over spending on the Predictions segment but also signals possible upside if earnings improve.

02

Market read

The target cut may influence short‑term trading decisions for DKNG and comparable betting stocks.

03

What to watch

Potential cost overruns in the Predictions business and competitive pressure from Kalshi.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

DraftKings has fallen 42% since its January high amid weaker-than‑expected revenue and rising competition in prediction markets.

Company-level read

Ticker impact

$DKNGNeutralHigh confidence
Context

Needham cut DraftKings' price target to $30 from $35, marking the second reduction this year and indicating a potential rebound opportunity.

Expected impact

likely upward pressure as the $30 target sits above the current price

Evidence & confidence

The new target is 44% above the recent close, implying analysts see upside potential if earnings meet forecasts.

Market effects

The downgrade may prompt re‑evaluation of other sports‑betting and prediction‑market firms.

U.S. discretionary consumer sector sees modest attention.

Limited to investors tracking U.S. online gambling stocks.

Counterpoint

Some investors may view the target cut as a buying opportunity given the stock's steep decline.

Key entities

  • DraftKings

    U.S. online sports betting and gaming operator (NASDAQ:DKNG).

  • Needham & Company

    Equity research firm that issued the price‑target change.

Related articles

$DKNGMed

DraftKings Scrutiny Grows in Louisiana, Ohio and Congress

DraftKings faces scrutiny from regulators in Louisiana and Ohio, and Congress, due to reports of targeting losing bettors. The Louisiana Gaming Control Board delayed the company's license renewal for four months to investigate. DraftKings disputes the allegations, stating its responsible gaming system worked as intended. The company also faces a proposed class action lawsuit alleging app design exploits compulsive bettors.

$DKNGMed

DraftKings, FanDuel Halt Utah Sports Event Contracts

DraftKings and FanDuel have halted sports, political, and novelty event contracts in Utah due to legal concerns. The move follows criminal charges against Kalshi, a prediction market, by the Utah Attorney General's Office. Both companies will still allow financial event contracts, including those related to stocks, commodities, and cryptocurrency. DraftKings made the change on Oct. 28, while FanDuel will implement it on Oct. 29.

$DKNGMed

Class action suit against FanDuel and DraftKings filed in Louisiana

A class action lawsuit was filed in Louisiana against FanDuel and DraftKings, alleging their apps exploit addictive behavior. The suit also names two casino licensees. Plaintiffs seek refunds and damages, citing a 75% market share for the two companies in 2023. The lawsuit claims 96% of customers lose money, driving the need for addictive design.

$DKNGMed

Morningstar: DraftKings Trading Well Below Fair Value Estimate

DraftKings (DKNG) shares are down 40% YTD, but Morningstar analyst Dan Wasiolek argues the stock is undervalued, with a $39 fair value estimate. Despite regulatory uncertainty, Morningstar rates it five stars, forecasting 8.1% sales and 24.9% EBITDA growth from 2026-2035. The NBA's crackdown on player proposition markets is not expected to hinder sports betting demand.